Vykat XR (diazoxide choline-extended release): a new FDA-approved treatment for hyperphagia in Prader-Willi syndrome
The first FDA-approved medication specifically targets excessive hunger in Prader-Willi Syndrome, addressing the life-threatening core symptom this rare condition lacked treatment for.
Vykat XR (diazoxide choline-extended release) is the first FDA-approved drug specifically targeting hyperphagia in Prader-Willi Syndrome (PWS), a life-threatening ultra-rare neurodevelopmental condition where hyperphagia-driven obesity is the leading cause of morbidity and mortality. This approval marks a significant milestone for a disease that has had no approved pharmacologic therapy for its core symptom for the entirety of its described history.
What the study was
- Study design
- Commentary/regulatory review of FDA approval
- Population
- Individuals aged ≥4 years with Prader-Willi Syndrome
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Annals of Medicine and Surgery
Why it surfaced
First-ever FDA-approved pharmacologic therapy for hyperphagia in PWS — a major regulatory milestone for an ultra-rare disease with extreme unmet need. NOVEL_TREATMENT flag elevates to HIGH regardless of lower score from commentary design. PWS hyperphagia causes severe obesity, metabolic complications, and early mortality.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.